Linked Life Data

20027355

Source:http://linkedlifedata.com/resource/pubmed/id/20027355

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-12-22
pubmed:abstractText
The use of ultralow doses of antibodies to prostate-specific antigen (afala) for long-term treatment of benign prostatic hyperplasia in patients with moderate symptoms rapidly and effectively reduces irritative and obstructive symptoms, significantly decreases residual urine volume, and increases the rate of urination. Afala therapy is indicated for patients with stage I-II benign prostatic hyperplasia of moderately pronounced symptoms.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1573-8221
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
148
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
308-11
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Experience of long-term afala treatment in benign prostatic hyperplasia.
pubmed:affiliation
Siberian State Medical University, Federal Agency for Health Care and Social Development, Tomsk.
pubmed:publicationType
Journal Article, Clinical Trial